Sea Mild Biotechnology Co., Ltd.
Sea Mild Biotechnology Co., Ltd. manufactures and sells paints, coatings, and detergents in Taiwan. It offers laundry, household, and personal detergent, as well as epidemic prevention products under the Sea Mild Biotech brand name. The company was established in 2007 is headquartered in Taoyuan City, Taiwan.
Sea Mild Biotechnology Co., Ltd. (7516) - Total Assets
Latest total assets as of June 2025: NT$281.93 Million TWD
Based on the latest financial reports, Sea Mild Biotechnology Co., Ltd. (7516) holds total assets worth NT$281.93 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sea Mild Biotechnology Co., Ltd. - Total Assets Trend (2016–2024)
This chart illustrates how Sea Mild Biotechnology Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sea Mild Biotechnology Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Sea Mild Biotechnology Co., Ltd.'s total assets of NT$281.93 Million consist of 84.5% current assets and 15.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 32.4% |
| Accounts Receivable | NT$63.62 Million | 24.8% |
| Inventory | NT$58.01 Million | 22.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$8.74 Million | 3.4% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sea Mild Biotechnology Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sea Mild Biotechnology Co., Ltd.'s current assets represent 84.5% of total assets in 2024, an increase from 34.5% in 2016.
- Cash Position: Cash and equivalents constituted 32.4% of total assets in 2024, up from 5.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 24.8% of total assets.
Sea Mild Biotechnology Co., Ltd. Competitors by Total Assets
Key competitors of Sea Mild Biotechnology Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥3.66 Billion |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$8.26 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥2.20 Billion |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥3.08 Billion |
|
Dencare (Chongqing) Oral Care Co. Ltd. A
SHE:001328
|
China | CN¥1.90 Billion |
|
Qingdao Kingking Applied Chemistry Co Ltd
SHE:002094
|
China | CN¥3.19 Billion |
|
C&S Paper Co Ltd
SHE:002511
|
China | CN¥9.17 Billion |
|
Anhui Deli Household Glass Co Ltd
SHE:002571
|
China | CN¥3.08 Billion |
Sea Mild Biotechnology Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Sea Mild Biotechnology Co., Ltd. generates 1.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Sea Mild Biotechnology Co., Ltd. generates $ 12.49 in net profit.
Sea Mild Biotechnology Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.26 | 1.66 |
| Quick Ratio | 1.16 | 0.99 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$73.13 Million | NT$ 40.94 Million | NT$ 67.08 Million |
Sea Mild Biotechnology Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Sea Mild Biotechnology Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.68 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 34.5% |
| Total Assets | NT$256.11 Million |
| Market Capitalization | $4.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sea Mild Biotechnology Co., Ltd.'s assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sea Mild Biotechnology Co., Ltd.'s assets grew by 34.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sea Mild Biotechnology Co., Ltd. (2016–2024)
The table below shows the annual total assets of Sea Mild Biotechnology Co., Ltd. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$256.11 Million | +34.54% |
| 2023-12-31 | NT$190.36 Million | +20.72% |
| 2022-12-31 | NT$157.69 Million | -6.27% |
| 2021-12-31 | NT$168.23 Million | -32.45% |
| 2020-12-31 | NT$249.04 Million | -31.43% |
| 2019-12-31 | NT$363.17 Million | +15.43% |
| 2018-12-31 | NT$314.64 Million | -6.90% |
| 2017-12-31 | NT$337.94 Million | +6.32% |
| 2016-12-31 | NT$317.86 Million | -- |